Vaccine manufacturing partners
Improving vaccine manufacture and stability
Whilst vaccine development research focuses initially on formulation of a vaccine with protective efficacy in animal models, the large-scale manufacture of vaccines requires detailed investigation and optimisation of vaccine component stability, production yield and scale and cost of GMP manufacture.
AVRA will collaborate with the existing capabilities (e.g. NCRIS, CSIRO, and commercial contract manufacturing organisations) and inform future investment and roadmap strategies to support Advanced Biomanufacturing facilities for end-to-end vaccine development.